Digital therapeutics (DTx), which provide evidence-based interventions through software programs, could benefit patients with nonalcoholic fatty liver disease (NAFLD), according to a new review.
Few studies have directly focused on DTx for NAFLD, but recent research about lifestyle interventions delivered via smartphone apps or web-based platforms could point to future possibilities, the authors write.
“Although lifestyle interventions have been shown to result in positive outcomes among patients with NAFLD, the success rate of the interventions and the sustainability of a healthy lifestyle for patients are issues that need to be addressed,” Junping Shi, MD, PhD, a professor of medicine at the Affiliated Hospital & Institute of Hepatology and Metabolic Disease at Hangzhou Normal University in China, and colleagues, write.